Compare Las Vegas Sands Corp. (LVS) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Vir Biotechnology Inc. Common Stock — how do they compare? Las Vegas Sands Corp. trades at $37.07 (market cap $23.99B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Las Vegas Sands Corp. is far larger — about 13.3× Vir Biotechnology Inc. Common Stock's market cap, and Las Vegas Sands Corp. pays a 3.24% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 73 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| LVS | VIR | |
|---|---|---|
Market Cap | $23.99B | $1.80B |
Volume | 5,076,550 | 1,782,836 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $11.78 |
52-Week Low | $35.81 | $5.12 |
Typical Hold Time | 73 Days | 0 Days |
Enterprise Value | $35.88B | $1.36B |
Dividend Yield | 3.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $37.02, up 2.41% today, but faces bearish technical signals with strong selling pressure on moving averages. The company shows solid fundamentals with revenue growth from $13.02B in 2025 to projected $13.7B in 2026, net margins around 12.5%, and attractive valuation with P/E of 14.36. Recent earnings show mixed results with Q2 2026 missing expectations after two consecutive beats. Analysts maintain strong buy consensus with $58.89 price target representing 59% upside potential.
LVS presents compelling value with strong analyst support and reasonable valuations, though technical weakness and high debt levels pose near-term risks. The company's consistent revenue growth and Macao recovery provide upside catalysts, but investors should monitor debt management and gaming regulatory environment. The significant gap between current price and analyst targets suggests substantial potential reward for risk-tolerant investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Vir Biotechnology Inc. Common Stock
Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →
